Goals
Prior to the founding of FCF, fibrolamellar carcinoma received minimal research attention. Since then, FCF has committed over $8 million to fund research studies conducted by many of the most prestigious and innovative research and academic institutions in the country. FCF-funded research has included a broad range of basic, translational and clinical studies (Click here to view an explanation of these three types of research).
As a leading funder of FLC research, our goal is to transform the fibrolamellar research landscape. By supporting cutting-edge research, actively recruiting new investigators to the disease, and working together to understand the origin and development of FLC, we hope to create more effective therapies and ultimately find a cure for the disease.
Research Approach
As a foundation, our research funding decisions are driven by three simple principals:
Our main objective is to find a cure for FLC. Because so much is still unknown about the disease, finding that cure requires:
- Funding a range of clinical, translational and basic research
- Taking educated risks, since not all initiatives will be successful.
We want our investments to make a difference and help bridge existing research gaps. With so much to be done, we:
- Prefer to support promising projects less likely to get traditional funding
- Prioritize seed funding of projects with potential long-term payoffs
- Avoid funding redundant efforts or displacing existing funding sources.
We believe the fastest path to a cure requires researchers to work together collaboratively – rapidly sharing information, materials, and expertise. We:
- Encourage collaboration between scientists and institutions with our grants program.
- Invite FLC researchers to a biennial research summit where they can share ideas, resources, and solutions, and help shape FCF’s research agenda.